Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

BACKGROUND: Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other infla...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S, Schoels, Monika M, Nishimoto, Norihiro, Breedveld, Ferdinand C, Burmester, Gerd R, Dougados, Maxime, Emery, Paul, Ferraccioli, Gianfranco, Gabay, Cem, Gibofsky, Allan, Gomez-Reino, Juan Jesus, Jones, Graeme, Kvien, Tore K, Murakami, Miho, Betteridge, Neil, Bingham, Clifton O, Bykerk, Vivian, Choy, Ernest H, Combe, Bernard, Cutolo, Maurizio, Graninger, Winfried, Lanas, Angel, Martin-Mola, Emilio, Montecucco, Carlomaurizio, Ostergaard, Mikkel, Pavelka, Karel, Rubbert-Roth, Andrea, Sattar, Naveed, Scholte-Voshaar, Marieke, Tanaka, Yoshiya, Trauner, Michael, Valentini, Gabriele, Winthrop, Kevin L, de Wit, Maarten, van der Heijde, Désirée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Consensus Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595138/
https://www.ncbi.nlm.nih.gov/pubmed/23172750
http://dx.doi.org/10.1136/annrheumdis-2012-202469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595138/
https://www.ncbi.nlm.nih.gov/pubmed/23172750
http://dx.doi.org/10.1136/annrheumdis-2012-202469

Ejemplares similares